Clinical Trial Update: Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella [Phase 1]

View source ↗

Summary

Phase 1 study assessing the safety and reactogenicity of a Shigella bioconjugate vaccine developed by GlycoVaxyn AG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• Shigella bioconjugate vaccine (GlycoVaxyn) (Shigella bioconjugate vaccine)

Snippet

Sponsor: GlycoVaxyn AG | Conditions: Shigellosis | Phase 1 | Status: COMPLETED